Search Within

Raajit Kumar Rampal

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (29)
  2. Meeting Abstract (24)
Groups
  1. Adult Leukemia (53)
  2. Center for Hematologic Malignancies (53)
  3. Department of Medicine (53)
  4. Hematologic Malignancies, Division of (53)
  5. Sloan Kettering Institute Postdocs (53)
  6. GSK Faculty (50)

More Groups

People
  1. Ross Levine (28)
  2. Omar Abdel-Wahab (24)
  3. Benjamin Durham (13)
  4. Maria Arcila (12)
  5. Martin Tallman (11)
  6. Minal Patel (11)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (2)
  4. 2021 (4)
  5. 2020 (7)
  6. 2019 (2)

More Years

Publications
  1. Blood (21)
  2. Haematologica (4)
  3. Cancer Discovery (3)
  4. Blood Advances (2)
  5. Cancer Cell (2)
  6. Journal for ImmunoTherapy of Cancer (2)

More Publications

Publishers
  1. American Society of Hematology (23)
  2. American Association for Cancer Research (5)
  3. Ferrata Storti Foundation (4)
  4. Nature Publishing Group (4)
  5. Cell Press (3)
  6. American Association for the Advancement of Science (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • LSD1 inhibitor CPI-482 shows efficacy and prolongs survival in mouse models of AML and post-MPN AML in the context of constitutive JAK-STAT pathway activation
    Meeting Abstract

    Rampal, R. K.; McGrath, J. P.; Krishnan, A.; Li, B.; Xiao, W.; Nikom, D.; Wang, J.; Levine, R. L.; Trojer, P.
    Blood (2020)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Pourpe, S.; Ghosh, A.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J. J.; Pourpe, S.; Ghosh, A.; Bozkus, C. C.; Mangarin, L. M. B.; Redmond, D.; Verma, S.; Schad, S.; more...
    Journal of Immunology (2020)

    Fulltext@MSK | Save
  • PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2(V617F)-mutant MPN
    Journal Article

    Pastore, F.; Bhagwat, N.; Pastore, A.; Radzisheuskaya, A.; Karzai, A.; Krishnan, A.; Li, B.; Bowman, R. L.; Xiao, W.; Viny, A. D.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Single-cell mutation analysis of clonal evolution in myeloid malignancies
    Journal Article

    Miles, L. A.; Bowman, R. L.; Merlinsky, T. R.; Csete, I. S.; Ooi, A. T.; Durruthy-Durruthy, R.; Bowman, M.; Famulare, C.; Patel, M. A.; Mendez, P.; more...
    Nature (2020)

    Fulltext@MSK | Save
  • Neurologic and oncologic features of Erdheim-Chester disease: A 30-patient series
    Journal Article

    Bhatia, A.; Hatzoglou, V.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B. H.; Dogan, A.; Ozkaya, N.; Yabe, M.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
    Journal Article

    Santos, F. P. S.; Getta, B.; Masarova, L.; Famulare, C.; Schulman, J.; Datoguia, T. S.; Puga, R. D.; de Melo Alves Paiva, R.; Arcila, M. E.; Hamerschlak, N.; more...
    Leukemia (2020)

    Fulltext@MSK | Save
  • Landscape of TP53 mutations in MPN
    Meeting Abstract

    Farnoud, N.; Famulare, C.; Papaemmanuil, E.; McGovern, E.; Medina, J.; Arango Ossa, J. E.; Rampal, R. K.; Li, B.; Levine, R. L.; Mascarenhas, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy of MEK inhibition in patients with histiocytic neoplasms
    Journal Article

    Diamond, E. L.; Durham, B. H.; Ulaner, G. A.; Drill, E.; Buthorn, J.; Ki, M.; Bitner, L.; Cho, H.; Young, R. J.; Francis, J. H.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Prognostic impact of activating mutations of the NRAS/KRAS genes in patients with primary and post-essential thrombocythemia (ET)/polycythemia vera (PV) myelofibrosis (MF)
    Meeting Abstract

    Santos, F. P. S.; Getta, B.; Masarova, L.; Famulare, C.; Schulman, J.; Puga, R. D.; Paiva, R. D. A.; Hamerschlak, N.; Kantarjian, H. M.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save